According to the Zhitong Finance APP, Frontier Biotechnologies (688221.SH) announced that its research product FB3002 (a hot melt adhesive patch for treating musculoskeletal joint pain) has received the "Acceptance Notice" for the generic drug marketing license application issued by the National Medical Products Administration.

FB3002, a loxoprofen sodium patch, is a high-end generic drug for treating musculoskeletal joint pain. The active ingredient in FB3002 is loxoprofen sodium, which is a non-steroidal anti-inflammatory analgesic. Its mechanism of action is to inhibit the activity of cyclooxygenase, thereby suppressing the synthesis of prostaglandins, resulting in good analgesic and anti-inflammatory effects, particularly strong analgesic effects. The patch type is a hot melt adhesive patch, which has advantages over traditional Chinese medicine patches, such as low irritability and allergenicity, no pungent odor, good adhesion, good skin extensibility, and the ability to be applied to active joints; compared to ordinary gel patches, hot melt adhesive patches have better adhesion, are not easy to fall off, have a thinner dosage form, and are more convenient to use